California Public Employees Retirement System reduced its position in Guardant Health, Inc. (NASDAQ:GH – Get Rating) by 5.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,778 shares of the company’s stock after selling 9,215 shares during the quarter. California Public Employees Retirement System’s holdings in Guardant Health were worth $6,486,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. HM Payson & Co. boosted its holdings in shares of Guardant Health by 100.0% in the 1st quarter. HM Payson & Co. now owns 1,000 shares of the company’s stock worth $66,000 after purchasing an additional 500 shares in the last quarter. SeaCrest Wealth Management LLC purchased a new stake in Guardant Health during the 2nd quarter valued at about $48,000. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in Guardant Health during the 1st quarter valued at about $89,000. CWM LLC lifted its holdings in Guardant Health by 73.6% in the 2nd quarter. CWM LLC now owns 1,734 shares of the company’s stock worth $70,000 after buying an additional 735 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in Guardant Health in the 1st quarter worth approximately $245,000. 89.36% of the stock is currently owned by hedge funds and other institutional investors.
Guardant Health Stock Up 6.5 %
GH stock opened at $50.07 on Friday. Guardant Health, Inc. has a twelve month low of $27.65 and a twelve month high of $111.48. The company has a quick ratio of 6.10, a current ratio of 6.46 and a debt-to-equity ratio of 6.82. The firm has a market cap of $5.13 billion, a PE ratio of -8.44 and a beta of 0.63. The business has a 50 day moving average of $49.99 and a 200 day moving average of $47.13.
Insider Activity at Guardant Health
Analyst Upgrades and Downgrades
GH has been the subject of several research analyst reports. Piper Sandler cut Guardant Health from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $65.00 to $50.00 in a report on Tuesday, November 1st. OTR Global cut Guardant Health to a “positive” rating in a report on Monday, August 1st. Morgan Stanley dropped their price objective on Guardant Health from $85.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, August 8th. JPMorgan Chase & Co. dropped their price objective on Guardant Health from $100.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, November 18th. Finally, The Goldman Sachs Group decreased their target price on Guardant Health from $80.00 to $70.00 and set a “buy” rating for the company in a research report on Friday, November 4th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and an average target price of $99.60.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.